{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-26-009744","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2026-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.277308+00:00","generated_at":"2026-05-15T00:16:26.225415+00:00","sec_items":["2.02","8.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"medium","headline":"Tonix reports preliminary Q1 net loss $40.8M, cash $185.5M, revenue $6.9M","bullets":["Net loss for Q1 2026 was ~$40.8M, up from $16.8M in Q1 2025; revenue rose to $6.9M from $2.4M, led by TONMYA ($3.7M).","Cash and equivalents at March 31, 2026: $185.5M; common shares outstanding as of April 30, 2026: 15,540,801.","Net cash used in operations was $40.2M in Q1 2026 vs $16.6M in Q1 2025; capex was $1.7M vs $6,000.","Raised $17.4M net from equity offerings in Q2 2026; cash runway expected into Q2 2027.","Preliminary results subject to revision; final Q1 2026 10-Q expected on or about May 11, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-26-009744","json":"https://secwatch.observer/filing/0001999371-26-009744.json","markdown":"https://secwatch.observer/filing/0001999371-26-009744.md","text":"https://secwatch.observer/filing/0001999371-26-009744.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126009744/0001999371-26-009744-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126009744/tnxp-8k_050126.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:16:26.225415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1d574967e67fa7cb10d491ca987ee048a3bf2635","claim":"Tonix Pharmaceuticals Holding Corp. reported quarter ended March 31, 2026 results: revenue approximately $6.9 million, net income approximately $40.8 million.","evidence_excerpt":"to $16.8 million for the quarter ended March 31, 2025. · The Company’s net revenue from sales of its marketed products for the quarter ended March 31, 2026, was approximately $6.9 million compared to $2.4 million for the quarter ended March 31, 2025. o Net revenue from sales of Zembrace® SymTouch ® and Tosymra ® for the quarter ended March 31, 2026, was","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126009744/0001999371-26-009744-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2026"},{"label":"Revenue","value":"approximately $6.9 million"},{"label":"Net income","value":"approximately $40.8 million"},{"label":"Result","value":"preliminary results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}